# Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

> **NCT03331198** · PHASE1,PHASE2 · RECRUITING · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 320 (estimated)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Small Lymphocytic

## Interventions

- **BIOLOGICAL:** JCAR017 (lisocabtagene maraleucel)
- **BIOLOGICAL:** JCAR017 (lisocabtagene maraleucel) + ibrutinib
- **BIOLOGICAL:** JCAR017 (lisocabtagene maraleucel) + venetoclax

## Key facts

- **NCT ID:** NCT03331198
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-27
- **Primary completion:** 2027-11-26
- **Final completion:** 2027-11-26
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331198, "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT03331198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*